Archive | July, 2014

Dr. Michael Har-Noy’s “Mirror Effect” Is A Truly Unique Approach to Cancer Treatment

14 Jul

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., says that the “Mirror EffectTM” is a proprietary immunologic treatment that has finally been able to separate the beneficial graft versus tumor (GVT) response of an allogeneic bone marrow transplant (BMT) from the deadly graft versus host (GVHD) complication. The separation of the GVT and GVHD processes has been called the “Holy Grail” of cancer treatment.

Dr. Michael Har-Noy tells us that the answer was to design a T-cell infusion that would mimic the immunologic responses caused by the transplanted donor cells but that would be ultimately controlled by the patient’s own immune cells. This proprietary response, termed the “Mirror EffectTM”, could theoretically produce the curative response of a BMT without the lethal complication of GVHD.

Dr. Michael Har-Noy says that the Mirror EffectTM process reverses the intimately related GVT and GVHD mechanisms that arise from the infused donor cells. This effect thus arises from the host immune response rather than from the transplanted cells, thus precipitating a host versus tumor (HVT) response that is associated with the non-toxic host versus graft (HVG) rejection process. To initiate the Mirror EffectTM reaction, T-cells from a normal donor are infused into a cancer patient. Dr. Michael Har-Noy says that these infused cells prompt the patient’s immune response to attack the malignant cells (HVT effect) and create an extremely inflammatory environment which incapacitates the tumor’s ability to evade the patient’s immune response.

Dr. Michael Har-Noy says that since the HVT response must be linked to a HVG rejection mechanism, the patient needs have an intact immune system that can rise up and reject the donor T-cells. Additionally, since graft rejection (HVG) is the desired response, the donor cells are also ideally intentionally mismatched to the recipient. Dr. Michael Har-Noy says that this is a vital and much-needed advancement over allogeneic BMT treatments, where only one third of potential recipients have a suitably matched donor.

The Mirror EffectTM, notes Dr. Michael Har-Noy, therefore involves the infusion of intentionally mismatched donor cells into a cancer patient that has received no pretreatment. The infused cells are then rejected by the patient’s immune system. This HVG rejection is the “mirror” of the deadly GVHD but has no toxicity. The HVG mechanism precipitates host-mediated tumor destruction (HVT), which is the “mirror” of the GVT process. Dr. Michael Har-Noy concludes that the Mirror EffectTM imitates the desired GVT effect of an allogeneic BMT while simultaneously avoiding the often-fatal toxicity of GVHD.

Dr. Michael Har-Noy feels that the Mirror EffectTM may be the beginning an entire new field of oncology. Please visit for more information on Dr. Michael Har-noy’s ongoing clinical trials.


Dr. Michael Har-Noy Has A Patent Portfolio of Virtually Limitless Value

9 Jul

Conventional cancer therapies, such as chemotherapy, surgery, and radiation, cannot target and destroy every metastatic cancer cell in a patient’s body. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, says that a patient’s natural immunity, if conditioned properly, may be able to do this. Dr. Michael Har-Noy indicates that if one could somehow condition a patient’s immune response so that it could find and eradicate malignant cells, an actual complete cure of the disease may be possible.

Over the past several years, Dr. Michael Har-Noy has developed a proprietary treatment he has termed the “Mirror EffectTM. The Mirror EffectTM technology is unique in that it both empowers a patient’s immune         response to target malignant cells and disrupts the tumor’s ability to evade this response.   The creation of the Mirror EffectTM and the development of the drugs that utilize it have the capacity to create an entire new field of oncology. Dr. Michael Har-Noy goes on to say that patenting and marketing these therapies could be both tremendously beneficial to cancer patients and immensely profitable for a company.

Dr. Michael Har-Noy has been working with his patent lawyers to construct a portfolio that protects the immense scope, depth, and detail of the Mirror EffectTM and outlines its use to condition a patient’s immune system to fight some of the most refractory conditions described in the medical literature. Dr. Michael Har-Noy notes that the patent portfolio he is creating entails not only protection of his company’s drugs and synthesizing methods but also has the potential to spawn an entirely new industry based on manipulating the human immune response.

Ultimately, Dr. Michael Har-Noy’s patent portfolio will probably start a new field of oncologic therapy and radically alter the way malignancies are treated. Patent attorneys have compared potential impact of Dr. Michael Har-Noy’s portfolio to that of the double-clicking of a mouse on a user interface on a computer screen. This double-clicking technology formed the foundation of the multi-billion dollar internet advertising industry. Dr. Michael Har-Noy believes his new technology will introduce an entirely new field of oncology and forever change the way cancer is treated, and that his Mirror EffectTM idea will therefore prove to be of virtually limitless value.